Evidence mapPaperPMID 35142107Full record

ReviewWIREs mechanisms of disease2022

New developments in the biology of fibroblast growth factors.

David M Ornitz, Nobuyuki Itoh

Open access · greenAbstract readReview
In one paragraph

Review in WIREs mechanisms of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 141 citations in OpenAlex.

  1. Review
  2. Blockade of FGFR1 Trafficking to the Cell Surface Results in the Partial Mistargeting of the Receptor to Peroxisomes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. FGF family in health and disease.Molecular biomedicine · 2026
    Review
  7. Article
  8. International journal of molecular sciences · 2026
    Article
  9. In Vivo Expression of an SCA27A-LinkedThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  10. [Advances on efficacy and mechanisms of acid fibroblast growth factor for promoting injured tissue repair].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective.Journal of mammary gland biology and neoplasia · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

David M OrnitzDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0003-1592-7629
Nobuyuki ItohKyoto University Graduate School of Pharmaceutical Sciences, Sakyo, Kyoto, Japan.
Kyoto University · JPWashington University in St. Louis · US

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
RESOURCE BASED CENTER FOR MUSCULOSKELETAL BIOLOGY AND MEDICINEP30AR074992 · WASHINGTON UNIVERSITY · 2025 to 2025
$641k
NCATS NIH HHS UL1 TR002345NHLBI NIH HHS R01 HL111190NHLBI NIH HHS R01 HL154747NIAMS NIH HHS P30 AR057235NIAMS NIH HHS P30 AR074992NICHD NIH HHS R21 HD098872NIH HHS HD09887202NIH HHS HL111190NIH HHS HL154747NIH HHS UL1TR002345
6 · The paper itself

Abstract

The fibroblast growth factor (FGF) family is composed of 18 secreted signaling proteins consisting of canonical FGFs and endocrine FGFs that activate four receptor tyrosine kinases (FGFRs 1-4) and four intracellular proteins (intracellular FGFs or iFGFs) that primarily function to regulate the activity of voltage-gated sodium channels and other molecules. The canonical FGFs, endocrine FGFs, and iFGFs have been reviewed extensively by us and others. In this review, we briefly summarize past reviews and then focus on new developments in the FGF field since our last review in 2015. Some of the highlights in the past 6 years include the use of optogenetic tools, viral vectors, and inducible transgenes to experimentally modulate FGF signaling, the clinical use of small molecule FGFR inhibitors, an expanded understanding of endocrine FGF signaling, functions for FGF signaling in stem cell pluripotency and differentiation, roles for FGF signaling in tissue homeostasis and regeneration, a continuing elaboration of mechanisms of FGF signaling in development, and an expanding appreciation of roles for FGF signaling in neuropsychiatric diseases. This article is categorized under: Cardiovascular Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology Congenital Diseases > Stem Cells and Development Cancer > Stem Cells and Development.

Indexed as

Fibroblast Growth FactorsReceptors, Fibroblast Growth FactorBiologyReceptor Protein-Tyrosine KinasesSignal TransductionFibroblast Growth FactorsReceptor Protein-Tyrosine KinasesReceptors, Fibroblast Growth Factorfibroblast growth factorsorganogenesisreceptor tyrosine kinaseregenerationtyrosine kinase inhibitors

Identifiers

PMID35142107
PMCPMC10115509
OpenAlexW4211019955

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.